Lumos Pharma to Participate in Upcoming Investor Conferences

Article Stock Quotes (1)

FREE Breaking News Alerts from StreetInsider.com!

StreetInsider.com Top Tickers, 8/23/2026

1. WMT
2. ROST
3. AAP
4. NVDA
5. SPY

6. BABA
7. AVGO
8. SPCX
9. DE
10. NTES

Get Alerts LUMO Hot Sheet

Price: $4.34 --0%

Overall Analyst Rating:
SELL (= Flat)

Join SI Premium – FREE

AUSTIN, Texas, March 10, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ: LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company will participate in the 34^th Annual Roth Conference and the Maxim 2022 Virtual Growth Conference in March.

Event:			34^th Annual Roth Conference – March 13-15
Presentation:			Live fireside chat March 14^th at 10:30 AM PDT / 1:30 PM EDT
Webcast link:			Here
Event:			Maxim 2022 Virtual Growth Conference – March 28-30
Presentation:			Pre-recorded presentation available beginning March 28^th at 9:00 AM (EDT)
Webcast link:			Here on the M-Vest conference platform

The webcasts for each presentation can also be found on the Company’s website under “Events & Presentations” in the Investors & Media section where a replay of each presentation will be also be available. Please contact your Roth or Maxim salesperson, or Lumos Pharma Investor Relations, to schedule one-on-one meetings with the management team during the conferences or thereafter.

About Lumos Pharma

Lumos Pharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics for rare diseases. Lumos Pharma was founded and is led by a management team with longstanding experience in rare disease drug development and received early funding from leading healthcare investors, including Deerfield Management, a fund managed by Blackstone Life Sciences, Roche Venture Fund, New Enterprise Associates (NEA), Santé Ventures, and UCB. Lumos Pharma’s lead therapeutic candidate is LUM-201, an oral growth hormone stimulating small molecule, currently being evaluated in a Phase 2 clinical trial, the OraGrowtH210 Trial, and a PK/PD trial, the OraGrowtH212 Trial, for the treatment of Pediatric Growth Hormone Deficiency (PGHD). If approved by the FDA, LUM-201 would provide an orally administered alternative to recombinant growth hormone injections that PGHD patients otherwise endure for many years of treatment. LUM-201 has received Orphan Drug Designation in both the US and EU. For more information, please visit https://lumos-pharma.com/.

Investor & Media Contact:

Lisa Miller
Lumos Pharma Investor Relations
512-792-5454
[email protected]

Source: Lumos Pharma, Inc.